Ingevity Corporation (NGVT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NGVT SEC filings page.
Ingevity Corporation (NGVT) reported $1.2B in revenue over the twelve months to Jun 30, 2026, up 10.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The operating engine remains resilient as sales shrink, but losses and extreme leverage have eroded the equity cushion.
Revenue contracted materially from FY2022 through FY2025 while operating margin widened to35.9% . Operating income remained near$420M across those years, indicating margin expansion—not sales growth—has preserved the operating earnings base.
The FY2025 net loss was
The equity base fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Ingevity Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Ingevity Corporation has an operating margin of 35.9%, meaning the company retains $36 of operating profit per $100 of revenue. This strong profitability earns a score of 94/100, reflecting efficient cost management and pricing power. This is up from 35.5% the prior year.
Ingevity Corporation's revenue declined 2.7% year-over-year, from $1.2B to $1.2B. This contraction results in a growth score of 24/100.
Ingevity Corporation has a moderate D/E ratio of 39.10. This balance of debt and equity financing earns a leverage score of 31/100.
Ingevity Corporation's current ratio of 1.33 indicates adequate short-term liquidity, earning a score of 35/100. The company can meet its near-term obligations, though with limited headroom.
Ingevity Corporation converts 23.4% of revenue into free cash flow ($273.5M). This strong cash generation earns a score of 77/100.
Ingevity Corporation posts a -562.6% return on equity (ROE), meaning it loses $563 for every $100 of shareholders' equity. This results in a returns score of 89/100. This is down from -220.4% the prior year.
Ingevity Corporation scores 2.89, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Ingevity Corporation passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Ingevity Corporation reported a net loss of $167.1M while generating $331.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Ingevity Corporation earns $5.35 in operating income for every $1 of interest expense ($418.7M vs $78.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Ingevity Corporation generated $314.1M in revenue in Q2 2026. This represents a decrease of 5.2% from the same quarter a year earlier. Against the prior quarter it is up 21.7%.
Ingevity Corporation reported $35.3M in net income in Q2 2026. This represents an increase of 124.1% from the same quarter a year earlier. Against the prior quarter it is down 41.0%.
Ingevity Corporation earned $1.00 per diluted share (EPS) in Q2 2026. This represents an increase of 124.9% from the same quarter a year earlier. Against the prior quarter it is down 39.8%.
Not reported for Q2 2026.
Cash & Balance Sheet
Ingevity Corporation recorded an outflow of $24.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 136.1% from the same quarter a year earlier. Against the prior quarter it is down 95.9%.
Ingevity Corporation held $97.4M in cash against $1.1B in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Ingevity Corporation's gross margin was 44.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 5.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.
Ingevity Corporation's net profit margin was 11.2% in Q2 2026, showing the share of revenue converted to profit. This is up 55.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.9 percentage points.
Ingevity Corporation's ROE was 75.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 196.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 78.5 percentage points.
Not reported for Q2 2026.
Capital Allocation
Ingevity Corporation invested $6.1M in research and development in Q2 2026. This represents a decrease of 12.9% from the same quarter a year earlier. Against the prior quarter it is down 9.0%.
Ingevity Corporation spent $34.5M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. Against the prior quarter it is down 34.0%.
Ingevity Corporation invested $10.3M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 15.6% from the same quarter a year earlier. It is unchanged from the prior quarter.
NGVT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $314.1M-5.2% | $258.0M+4.1% | $255.1M+88.1% | $333.1M-0.2% | $331.5M-15.1% | $247.9M-27.1% | $135.6M | $333.8M-25.2% |
| Cost of Revenue | $175.1M-14.0% | $141.6M+4.1% | $167.2M+560.9% | $199.2M-1.5% | $203.7M-23.8% | $136.0M-43.4% | $25.3M | $202.2M-36.2% |
| Gross Profit | $139.0M+8.8% | $116.4M+4.0% | $87.9M-20.3% | $133.9M+1.7% | $127.8M+3.7% | $111.9M+12.2% | $110.3M | $131.6M+2.0% |
| R&D Expenses | $6.1M-12.9% | $6.7M-4.3% | $7.4M+76.2% | $7.0M+12.9% | $7.0M-4.1% | $7.0M+2.9% | $4.2M | $6.2M-20.5% |
| SG&A Expenses | $39.0M-10.6% | $40.7M-2.9% | $41.6M+32.9% | $44.1M+16.4% | $43.6M+5.3% | $41.9M-11.2% | $31.3M | $37.9M-5.3% |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | $137.5M | $110.2M-0.2% |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | $162.7M | $136.4M-3.3% |
| Interest Expense | $14.2M-23.7% | $15.9M-18.0% | $21.9M-23.2% | $18.4M-22.7% | $18.6M-19.8% | $19.4M-13.0% | $28.5M | $23.8M+3.0% |
| Income Tax | $10.9M+127.1% | $6.8M-20.0% | -$26.5M-164.3% | $21.4M+229.2% | $4.8M+109.4% | $8.5M+153.5% | $41.2M | $6.5M-5.8% |
| Net Income | $35.3M+124.1% | $59.8M+191.7% | -$84.6M-609.6% | $43.5M+140.6% | -$146.5M+48.4% | $20.5M+136.6% | $16.6M | -$107.2M-525.4% |
| EPS (Basic) | $1.02+125.4% | $1.70+203.6% | -$2.34-608.7% | $1.20+140.7% | -$4.02+48.5% | $0.56+136.4% | $0.46+114.4% | -$2.95-521.4% |
| EPS (Diluted) | $1.00+124.9% | $1.66+196.4% | -$2.34-608.7% | $1.18+140.1% | -$4.02+48.5% | $0.56+136.4% | $0.46+114.5% | -$2.94-526.1% |
| Diluted Shares (Avg) | 35M-3.2% | 36M-1.8% | N/A | 37M+1.3% | 36M+0.3% | 37M+1.1% | N/A | 36M+0.3% |
NGVT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B-18.1% | $1.7B-19.7% | $1.7B-18.4% | $1.8B-17.1% | $1.9B-17.5% | $2.1B-19.9% | $2.0B-22.9% | $2.2B-20.1% |
| Current Assets | $543.8M+1.5% | $581.8M+9.8% | $454.2M-7.9% | $522.2M-18.0% | $536.0M-21.8% | $530.0M-20.8% | $493.2M-25.1% | $636.8M-13.3% |
| Cash & Equivalents | $97.4M+26.7% | $95.4M+33.4% | $78.1M+14.9% | $83.4M-38.5% | $76.9M-28.4% | $71.5M-19.2% | $68.0M-29.1% | $135.5M+60.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $154.0M-30.1% | $203.6M-17.0% | $186.0M-5.1% | $193.7M-25.8% | $220.3M-27.1% | $245.4M-24.6% | $195.9M-36.6% | $261.0M-32.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $4.3M0.0% | $4.3M-97.6% | $4.3M-97.5% | $4.3M-97.7% | $4.3M-97.6% | $180.7M-65.6% | $175.2M-66.8% | $186.9M-64.1% |
| Total Liabilities | $1.5B-15.2% | $1.6B-11.5% | $1.6B-11.3% | $1.7B-15.1% | $1.8B-11.8% | $1.8B-8.9% | $1.8B-8.3% | $2.0B-2.5% |
| Current Liabilities | $337.6M-14.1% | $409.4M+54.7% | $341.3M+29.2% | $411.6M+14.1% | $393.1M+9.9% | $264.6M-24.8% | $264.1M-27.2% | $360.8M+18.3% |
| Non-Current Liabilities | $1.2B-15.5% | $1.2B-22.8% | $1.3B-18.1% | $1.3B-21.5% | $1.4B-16.5% | $1.6B-5.5% | $1.6B-4.0% | $1.6B-6.1% |
| Long-Term Debt | $1.1B-14.5% | $1.1B-18.8% | $1.2B-13.3% | $1.2B-17.1% | $1.2B-11.8% | $1.3B-5.4% | $1.3B-3.1% | $1.4B-4.9% |
| Total Equity | $46.9M-61.1% | $38.9M-83.4% | $29.7M-84.8% | $138.1M-35.6% | $120.7M-57.6% | $234.6M-58.7% | $195.2M-69.1% | $214.5M-70.2% |
| Retained Earnings | $500.0M+12.1% | $464.7M-21.6% | $404.9M-29.2% | $489.5M-11.9% | $446.0M-32.7% | $592.5M-37.4% | $572.0M-42.9% | $555.4M-50.4% |
Not reported in any period shown, so not listed: Accounts Receivable.
NGVT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.8M-117.5% | -$2.0M-107.9% | $97.1M+50.5% | $129.7M+178.9% | $79.0M+166.0% | $25.4M+309.9% | $64.5M+39.6% | $46.5M-55.8% |
| Depreciation & Amortization | $22.0M-14.1% | $22.7M-8.8% | $27.9M+10.7% | $28.0M+6.9% | $25.6M-6.2% | $24.9M-15.9% | $25.2M-17.9% | $26.2M-14.4% |
| Stock-Based Compensation | N/A | $4.8M+17.1% | N/A | N/A | N/A | $4.1M-4.7% | N/A | N/A |
| Capital Expenditures | $10.3M-15.6% | $10.3M+3.0% | $23.6M-5.2% | $11.9M-33.9% | $12.2M-32.6% | $10.0M-39.8% | $24.9M-14.7% | $18.0M-46.3% |
| Free Cash Flow | -$24.1M-136.1% | -$12.3M-179.9% | $73.5M+85.6% | $117.8M+313.3% | $66.8M+475.9% | $15.4M+153.7% | $39.6M+132.9% | $28.5M-60.3% |
| Investing Cash Flow | $75.4M+2792.9% | $106.3M+1024.3% | -$15.1M+46.1% | -$28.1M-61.5% | -$2.8M+84.3% | -$11.5M+29.4% | -$28.0M-13.4% | -$17.4M+46.1% |
| Financing Cash Flow | -$37.6M+40.3% | -$61.8M-461.8% | -$83.4M+14.5% | -$94.8M-1404.8% | -$63.0M-711.7% | -$11.0M-147.0% | -$97.6M-1401.5% | -$6.3M+88.2% |
| Share Buybacks | $34.5M | $52.3M | $31.1M | $25.2M | $0 | $0 | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
NGVT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 44.3%+5.7pp | 45.1%0.0pp | 34.5%-46.9pp | 40.2%+0.8pp | 38.6%+7.0pp | 45.1%+15.8pp | 81.3% | 39.4%+10.5pp |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | 101.4% | 33.0%+8.3pp |
| Net Margin | 11.2%+55.4pp | 23.2%+14.9pp | -33.2%-45.4pp | 13.1%+45.2pp | -44.2%+28.4pp | 8.3%+24.7pp | 12.2% | -32.1%-37.8pp |
| Return on Equity | 75.3%+196.6pp | 153.7%+145.0pp | -284.8%-293.3pp | 31.5%+81.5pp | -121.4%-21.8pp | 8.7%+18.6pp | 8.5% | -50.0%-53.5pp |
| Return on Assets | 2.3%+10.1pp | 3.6%+2.6pp | -5.1%-5.9pp | 2.4%+7.2pp | -7.8%+4.7pp | 1.0%+3.2pp | 0.8% | -4.9%-5.8pp |
| Current Ratio | 1.61+0.2x | 1.42-0.6x | 1.33-0.5x | 1.27-0.5x | 1.36-0.6x | 2.00+0.1x | 1.87+0.1x | 1.76-0.6x |
| Debt-to-Equity | 22.52+12.3x | 27.83+22.1x | 39.10+32.2x | 8.39+1.9x | 10.24+5.3x | 5.68+3.2x | 6.86+4.7x | 6.52+4.5x |
| Asset Turnover | 0.200.0x | 0.160.0x | 0.15+0.1x | 0.180.0x | 0.180.0x | 0.120.0x | 0.07 | 0.150.0x |
| FCF Margin | -7.7%-27.8pp | -4.8%-11.0pp | 28.8%-0.4pp | 35.4%+26.8pp | 20.2%+17.2pp | 6.2%+14.7pp | 29.2% | 8.5%-7.5pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Ingevity Corporation NGVT | FY2025 | $1.2B | -$167.1M | -14.3% | $2.5B | 58/100 |
| Innospec Inc. IOSP | FY2025 | $1.8B | $116.6M | 6.6% | $2.4B | 51/100 |
| Minerals Technologies Inc MTX | FY2025 | $2.1B | -$18.4M | -0.9% | $2.1B | 50/100 |
| The Chemours Company CC | FY2025 | $5.8B | -$386.0M | -6.7% | $2.1B | 16/100 |
| Quaker Houghton KWR | FY2025 | $1.9B | -$2.5M | -0.1% | $2.8B | 44/100 |
| Ashland Inc. ASH | FY2025 | $1.8B | -$845.0M | -46.3% | $3.2B | 37/100 |
Where Ingevity Corporation Ranks
Frequently Asked Questions
What is Ingevity Corporation's annual revenue?
Ingevity Corporation (NGVT) reported $1.2B in total revenue for fiscal year 2025. This represents a -2.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ingevity Corporation's revenue growing?
Ingevity Corporation (NGVT) revenue declined by 2.7% year-over-year, from $1.2B to $1.2B in fiscal year 2025.
Is Ingevity Corporation profitable?
No, Ingevity Corporation (NGVT) reported a net income of -$167.1M in fiscal year 2025, with a net profit margin of -14.3%.
What is Ingevity Corporation's EBITDA?
Ingevity Corporation (NGVT) had EBITDA of $525.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Ingevity Corporation have?
As of fiscal year 2025, Ingevity Corporation (NGVT) had $78.1M in cash and equivalents against $1.2B in long-term debt.
What is Ingevity Corporation's gross margin?
Ingevity Corporation (NGVT) had a gross margin of 39.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Ingevity Corporation's operating margin?
Ingevity Corporation (NGVT) had an operating margin of 35.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Ingevity Corporation's net profit margin?
Ingevity Corporation (NGVT) had a net profit margin of -14.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Ingevity Corporation's return on equity (ROE)?
Ingevity Corporation (NGVT) has a return on equity of -562.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Ingevity Corporation's free cash flow?
Ingevity Corporation (NGVT) generated $273.5M in free cash flow during fiscal year 2025. This represents a 436.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ingevity Corporation's operating cash flow?
Ingevity Corporation (NGVT) generated $331.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Ingevity Corporation's total assets?
Ingevity Corporation (NGVT) had $1.7B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ingevity Corporation's capital expenditures?
Ingevity Corporation (NGVT) invested $57.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Ingevity Corporation spend on research and development?
Ingevity Corporation (NGVT) invested $28.4M in research and development during fiscal year 2025.
What is Ingevity Corporation's current ratio?
Ingevity Corporation (NGVT) had a current ratio of 1.33 as of fiscal year 2025, which is considered adequate.
What is Ingevity Corporation's debt-to-equity ratio?
Ingevity Corporation (NGVT) had a debt-to-equity ratio of 39.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ingevity Corporation's return on assets (ROA)?
Ingevity Corporation (NGVT) had a return on assets of -10.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ingevity Corporation's P/E ratio?
Ingevity Corporation (NGVT) trades at 46.1x earnings, its market capitalization divided by net income of $54.0M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Ingevity Corporation's price-to-sales ratio?
Ingevity Corporation (NGVT) trades at 2.1x sales, its market capitalization divided by revenue of $1.2B revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Ingevity Corporation's Altman Z-Score?
Ingevity Corporation (NGVT) has an Altman Z-Score of 2.89, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ingevity Corporation's Piotroski F-Score?
Ingevity Corporation (NGVT) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ingevity Corporation's earnings high quality?
Ingevity Corporation (NGVT) reported a net loss of $167.1M while generating $331.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Ingevity Corporation cover its interest payments?
Ingevity Corporation (NGVT) has an interest coverage ratio of 5.35x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Ingevity Corporation?
Ingevity Corporation (NGVT) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.